Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT03776006

Registry: TPLA for LUTS

Rationale: The treatment of lower urinary tract symptoms (LUTS) due to benign prostatic enlargement in men with transperineal laser ablation (TPLA) may offer advantages in functional outcomes and safety over current standard therapies. As the technique is relatively new, indications and outcomes for this treatment are subject of investigation. However, the technique is already applied outside clinical studies. Clinical information from these treatments can be useful for future research. The aim of this study is to collect data on patients treated with transperineal laser ablation of the prostate outside clinical trials and to provide data on safety and functional outcomes in these patients in order to improve treatment.

Objective: To assess long-term efficacy of transperineal laser ablation for lower urinary tract symptoms, to assess functional outcomes, to assess safety, to determine baseline patient characteristics, to collect information on possible differences between centres applying treatment of transperineal laser ablation and to explore the optimal treatment indications and possible limitations.

Study design: This is an international prospective observational study in which data is recorded of patients who are treated with transperineal laser ablation for lower urinary tract symptoms.

Study population: Male patients treated with transperineal laser ablation for lower urinary tract symptoms due to benign prostatic enlargement.

Main study parameters/endpoints: The primary endpoint of this study is long-term efficacy of transperineal laser ablation for lower urinary tract symptoms measured by the time until surgical retreatment.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male
  • Presenting with lower urinary tract symptoms
  • Indication for transperineal laser ablation
  • Signed informed consent form

Exclusion criteria

  • Age < 18 years
  • Previous or active treatment for prostate cancer (active surveillance is not seen as active treatment)

Treatment and study plan

Transperineal Laser Ablation

Procedure

Transperineal Laser Ablation of the Prostate

Other names: Echolaser X4

Primary outcomes

  1. Long-term treatment efficacy measured by the time until surgical retreatment.

    Time frame: 5 years following TPLA treatment

    The treatment effectiveness is measured by the time until the need for surgical retreatment. This is measured by the time between the TPLA treatment and retreatment indicated due to new micturion problems. The time is expressed in years.

Secondary outcomes

  1. Experienced functional efficacy measured by change in International Prostate Symptom Score

    Time frame: 12 months following TPLA treatment

    The experienced functional efficacy is measured by change in the International Prostate Symptom Score (IPSS). The IPSS is a is a self-administered scale of 7 questions concerning urinary symptoms plus one question concerning quality of life (QoL). Each of the seven symptoms includes the assignment of scores from 0 to 5. The total score can therefore range from 0 to 35 points (asymptomatic to very symptomatic). The patient's quality of life (QoL) will be evaluated separately.

  2. Objectified functional efficacy measured by change of maximum flow by uroflowmetry.

    Time frame: 12 months following TPLA treatment

    Change in maximum urinary flow rate after 12 months compared to baseline.

  3. Long-term treatment efficacy measured by the time until restart of urological medication.

    Time frame: 5 years following TPLA treatment

    The treatment effectiveness is measured by the time until the need for medical treatment due to new miction symptoms. This is measured by the time between the TPLA treatment and start of medical treatment for LUTS. The time is expressed in years.

  4. Procedural safety measuered by the incidence of TPLA procedure related adverse events, reported by the CTCAE v5.0..

    Time frame: 1 day following TPLA treatment

    Number of intraoperative adverse events using the CTCAE v5.0. Procedural safety is shown when no adverse events of grade 3 or higher.

  5. Treatment safety measured by adverse event incidence at 30 days, reported by the CTCAE v5.0

    Time frame: 30 days following TPLA treatment

    Number of adverse events using the CTCAE v5.0. Treatment safety is shown when no adverse events of grade 3b or higher are reported at 30 days post-TPLA treatment.

Study contacts

Contact information is provided by the study sponsor or research team.

H Beerlage, Prof.

CONTACT

[email protected]

+31 20 5664776

Sponsors and collaborators

Lead sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Other

Registry information

Official study title

Registry of Transperineal Laser Ablation for Treatment of Lower Urinary Tract Symptoms With Use of the Echolaser® Device: A Multicentre, International Registry to Evaluate the Treatment of LUTS in Terms of Long-term Efficacy, Functional Outcomes and Safety

Important dates

Study start
2019
Primary completion
2029
Study completion
2029
First posted
Dec 14, 2018
Registry last updated
Jan 18, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.